The Attributable Burden of Hypertension: Focus on CKD

  • Kenneth A. Jamerson
    Address correspondence to Kenneth A. Jamerson, MD, Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical Center, Domino Farms, Lobby M, 3rd Floor, 24 Frank Lloyd Wright Drive, Ann Arbor, MI 48106.
    University of Michigan Medical Center, Ann Arbor, MI; and Renal Division, University of Pennsylvania, Philadelphia, PA
    Search for articles by this author
  • Raymond R. Townsend
    University of Michigan Medical Center, Ann Arbor, MI; and Renal Division, University of Pennsylvania, Philadelphia, PA
    Search for articles by this author
      Hypertension is a worldwide risk factor for premature death and disability from heart disease, stroke, peripheral vascular disease, and kidney failure. Much is known about the role of elevated blood pressure as a contributor to diseases of the heart and brain, but the risk it confers specifically to the development and progression of kidney disease is less well appreciated. The kidney is unique among the target organs of elevated blood pressure because it both suffers damage and still contributes to the pathophysiologic sustenance of hypertension through many avenues. In this overview, we discuss high blood pressure from an epidemiologic standpoint, placing it in a nephrologic perspective and discuss some of the known and speculative mechanisms that link it to kidney damage.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lewis J.B.
        Blood pressure control in chronic kidney disease: is less really more?.
        J Am Soc Nephrol. 2010; 21: 1086-1092
        • Muntner P.
        • Anderson A.
        • Charleston J.
        • et al.
        Hypertension awareness, treatment, and control in adults with chronic kidney disease: results from the Chronic Renal Insufficiency Cohort (CRIC) Study.
        Am J Kidney Dis. 2009; 55: 441-451
        • MacMahon S.
        • Alderman M.H.
        • Lindholm L.H.
        • Liu L.
        • Sanchez R.A.
        • Seedat Y.K.
        Blood-pressure-related disease is a global health priority.
        Am J Hypertens. 2008; 21: 843-844
        • Eknoyan G.
        • Lameire N.
        • Barsoum R.
        • et al.
        The burden of kidney disease: improving global outcomes.
        Kidney Int. 2004; 66: 1310-1314
        • Heron M.
        • Hoyert D.L.
        • Murphy S.L.
        • Xu J.
        • Kochanek K.D.
        • Tejada-Vera B.
        Deaths: final data for 2006.
        Natl Vital Stat Rep. 2009; 57: 1-134
        • Omran A.R.
        The epidemiologic transition. A theory of the epidemiology of population change.
        Milbank Mem Fund Q. 1971; 49: 509-538
        • Chobanian A.V.
        Shattuck lecture. The hypertension paradox—more uncontrolled disease despite improved therapy.
        N Engl J Med. 2009; 361: 878-887
        • Mascie-Taylor C.G.
        • Karim E.
        The burden of chronic disease.
        Science. 2003; 302: 1921-1922
        • Lewington S.
        • Clarke R.
        • Qizilbash N.
        • Peto R.
        • Collins R.
        Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
        Lancet. 2002; 360: 1903-1913
        • Lawes C.M.
        • Vander H.S.
        • Rodgers A.
        Global burden of blood-pressure-related disease, 2001.
        Lancet. 2008; 371: 1513-1518
      1. 2009 WHO Global Health report. Available at: Accessed October 4, 2010.

        • Lopez A.D.
        • Mathers C.D.
        • Ezzati M.
        • Jamieson D.T.
        • Murray C.J.L.
        Global Burden of Disease and Risk Factors.
        University Press, New York, NY2006
        • Walker R.W.
        • McLarty D.G.
        • Kitange H.M.
        • et al.
        Stroke mortality in urban and rural Tanzania. Adult Morbidity and Mortality Project.
        Lancet. 2000; 355: 1684-1687
        • Klag M.J.
        • Whelton P.K.
        • Randall B.L.
        • et al.
        Blood pressure and end-stage renal disease in men.
        Clin Nephrol. 1996; 334: 13-18
        • Klag M.J.
        • Whelton P.K.
        • Randall B.L.
        • Neaton J.D.
        • Brancati F.L.
        • Stamler J.
        End-stage renal disease in African-American and white men. 16-year MRFIT findings.
        JAMA. 1997; 277: 1293-1298
        • Bakris G.L.
        • Williams M.
        • Dworkin L.
        • et al.
        Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.
        Am J Kidney Dis. 2000; 36: 646-661
        • Kearney P.M.
        • Whelton M.
        • Reynolds K.
        • Muntner P.
        • Whelton P.K.
        • He J.
        Global burden of hypertension: analysis of worldwide data.
        Lancet. 2005; 365: 217-223
        • Perera G.A.
        Hypertensive vascular disease; description and natural history.
        J Chronic Dis. 1955; 1: 33-42
      2. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.
        JAMA. 1967; 202: 1028-1034
      3. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg.
        JAMA. 1970; 213: 1143-1152
        • Castelli W.P.
        Epidemiology of coronary heart disease: the Framingham Study.
        Am J Med. 1984; 76: 4-12
        • Haider A.W.
        • Larson M.G.
        • Franklin S.S.
        • Levy D.
        Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study.
        Ann Intern Med. 2003; 138: 10-16
        • Kannel W.B.
        • Wolf P.A.
        • McGee D.L.
        • Dawber T.R.
        • McNamara P.
        • Castelli W.P.
        Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study.
        JAMA. 1981; 245: 1225-1229
        • Feldman H.I.
        • Appel L.J.
        • Chertow G.M.
        • et al.
        The Chronic Renal Insufficiency Cohort (CRIC) Study: design and methods.
        J Am Soc Nephrol. 2003; 14: S148-S153
        • Furth S.L.
        • Cole S.R.
        • Moxey-Mims M.
        • et al.
        Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study.
        Clin J Am Soc Nephrol. 2006; 1: 1006-1015
        • Lash J.P.
        • Go A.S.
        • Appel L.J.
        • et al.
        Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.
        Clin J Am Soc Nephrol. 2009; 4: 1302-1311
        • Imai E.
        • Matsuo S.
        • Makino H.
        • et al.
        Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods.
        Hypertens Res. 2008; 31: 1101-1107
        • Shishehbor M.H.
        • Oliveira L.P.
        • Lauer M.S.
        • et al.
        Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease.
        Am J Cardiol. 2008; 101: 1741-1746
        • Kopp J.B.
        • Smith M.W.
        • Nelson G.W.
        • et al.
        MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.
        Nat Genet. 2008; 40: 1175-1184
        • Kao W.H.
        • Klag M.J.
        • Meoni L.A.
        • et al.
        MYH9 is associated with nondiabetic end-stage renal disease in African Americans.
        Nat Genet. 2008; 40: 1185-1192
        • Freedman B.I.
        • Kopp J.B.
        • Langefeld C.D.
        • et al.
        The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.
        J Am Soc Nephrol. 2010; 21: 1422-1426
        • Barker D.J.
        Birth weight and hypertension.
        Hypertension. 2006; 48: 357-358
        • Barker D.J.
        The origins of the developmental origins theory.
        J Intern Med. 2007; 261: 412-417
        • Hill G.S.
        • Heudes D.
        • Jacquot C.
        • Gauthier E.
        • Bariety J.
        Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension.
        Kidney Int. 2006; 69: 823-831
        • Loutzenhiser R.
        • Griffin K.
        • Williamson G.
        • Bidani A.
        Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms.
        Am J Physiol Regul Integr Comp Physiol. 2006; 290: R1153-R1167
        • O’Rourke M.F.
        • Safar M.E.
        Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy.
        Hypertension. 2005; 46: 200-204
        • Klahr S.
        The kidney in hypertension–villain and victim.
        N Engl J Med. 1989; 320: 731-733
        • Wheatley K.
        • Ives N.
        • Gray R.
        • et al.
        Revascularization versus medical therapy for renal-artery stenosis.
        N Engl J Med. 2009; 361: 1953-1962
        • Bax L.
        • Woittiez A.J.
        • Kouwenberg H.J.
        • et al.
        Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.
        Ann Intern Med. 2009; 150: 840-841
        • Scarpioni R.
        • Michieletti E.
        • Cristinelli L.
        • et al.
        Atherosclerotic renovascular disease: medical therapy versus medical therapy plus renal artery stenting in preventing renal failure progression: the rationale and study design of a prospective, multicenter and randomized trial (NITER).
        J Nephrol. 2005; 18: 423-428
        • Schieppati A.
        • Remuzzi G.
        The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises.
        Kidney Int. 2003; 64: 1947-1955
        • Appel L.J.
        • Wright Jr., J.T.
        • Greene T.
        • et al.
        Intensive blood-pressure control in hypertensive chronic kidney disease.
        N Engl J Med. 2010; 363: 918-929